This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Is a Beat in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) is expected to report first-quarter 2018 results, on May 8 and provide updates on its pipeline candidates.
GW Pharma (GWPH) Q2 Earnings: Is a Turnaround in the Cards?
by Zacks Equity Research
GW Pharma (GWPH) is expected to report its fiscal second-quarter results next week. Investors focus is expected to be on commercialization plan for Epidiolex.
What's in Store for Intercept (ICPT) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Ocaliva sales when Intercept (ICPT) reports first-quarter results (expected on May 3).
Zoetis (ZTS) Gears Up for Q1 Earnings: What's in Store?
by Zacks Equity Research
Zoetis' (ZTS) top line in the first quarter is likely to be driven by continued demand for dermatology portfolio and product launches.
Will Segmental Revenues Aid Cooper's (COO) Q1 Earnings?
by Zacks Equity Research
CooperSurgical sales and broad product spectrum are key catalysts for Cooper's (COO) Q1 earnings. However, falling estimates of other segments are likely to mar prospects.
Is a Beat in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) will report its fourth-quarter results in early March. Investors focus is expected to be on pipeline updates.
Adverum Biotechnologies (ADVM) Jumps: Stock Rises 7.9%
by Zacks Equity Research
Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares nearly 8% on the day amid huge volumes.
What's in the Cards for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) will report its third-quarter results later this month. Investors focus is expected to be on pipeline updates.
Adverum Biotechnologies (ADVM) in Focus: Stock Moves 9.7% Higher
by Zacks Equity Research
Adverum Biotechnologies (ADVM) was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Marinus Stock Surges on Successful Phase II Epilepsy Study
by Zacks Equity Research
Marinus (MRNS) announced positive top-line data from a phase II study on its epilepsy candidate, ganaxolone, for treating CDKL5 disorder.
Is Adverum Biotechnologies an Incredible Momentum Stock? 3 Reasons Why ADVM Will Be Tough to Beat
by Zacks Equity Research
Adverum Biotechnologies (ADVM) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
What's in the Cards for Adverum (ADVM) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.
What's in Store for Adverum (ADVM) in Q1 Earnings?
by Zacks Equity Research
Adverum Biotechnologies, Inc (ADVM) is expected to report first-quarter 2017 results later this month.
Adverum (ADVM) to Post Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Adverum Biotechnologies, Inc (ADVM) is expected to report fourth-quarter 2016 results on Mar 2.